Current Status for Oral Platinum (IV) Anticancer Drug Development

Mi, Qian; Shu, Shunshun; Yang, Caixia; Gao, Chuan; Zhang, Xian; Luo, Xiao; Bao, Chonghuan; Zhang, Xia; Niu, Jun

doi:10.4236/ijmpcero.2018.72020

Cited by 19 publications

(13 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GSH, ascorbic acid, and cysteine residues) to give the corresponding more reactive Pt( ii ) drugs. 1 – 3 The Pt( iv ) drugs iproplatin, 4 , 5 ormaplatin, 6 satraplatin 7 and LA-12 8 have entered clinical trials, but none has yet received clinical approval. 9 A problem for Pt( iv ) drugs, which are activated by chemical reduction in the body, is that the extent and cell selectivity of activation are difficult to control since they rely on natural processes.…”

Section: Introductionmentioning

confidence: 99%

Axial functionalisation of photoactive diazido platinum(iv) anticancer complexes

Shi

Imberti

Clarkson

et al. 2020

Inorg. Chem. Front.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Axial functionalisation of photoactive diazido platinum(iv) anticancer complexes

Shi

Imberti

Clarkson

et al. 2020

Inorg. Chem. Front.

View full text Add to dashboard Cite

show abstract

“…However, their negative side‐effects and the risk of resistance remain a pressing matter in their clinical use. These issues drive the research and development of new metallotherapeutics, in many cases, divergent from the platinum‐based complexes . Copper is biocompatible and less toxic that non‐endogenous heavy metals, furthermore, copper is an interesting candidate for the treatment of cancers because of its bioavailability and the observation of increased copper level in cancer tissue .…”

Section: Introductionmentioning

confidence: 99%

Retracted: Studies of proteasome inhibition and antitumor activity by novel amino acid‐polypyridine‐copper complexes

Yang

Zhao

et al. 2019

Journal of Heterocyclic Chem

View full text Add to dashboard Cite

Five innovative ternary copper (II) complexes [Cu (OH‐PIP)(Phe)Cl](1), [Cu (OH‐PIP)(Gly)(H2O)]NO3·2H2O (2), [Cu (OH‐PIP)(Ala)(Cl)]·H2O (3), [Cu (OH‐PIP)(Met)]PF6·2H2O (4), and [Cu (OH‐PIP)(Gln)(H2O)]Cl·3H2O (5) have been synthesized and characterized by infrared spectroscopy, elemental analysis, and single crystal X‐ray diffraction analysis. X‐ray crystallography showed that all Cu atoms were five‐coordinated in a square‐pyramidal configuration. They are screened for in vitro cytotoxicity against a panel of human cancer cell lines CAL‐51, MDA‐MB‐231, HeLa, MCF‐7, SGC‐7901, A549, K562, and SMMC‐7721. The most promising results were achieved for complexes 1 to 5, with the IC50 values in the range of 0.082μM to 0.69μM (against CAL‐51 cell lines). The anticancer activities against CAL‐51, MDA‐MB‐231, and MCF‐7 were higher than that of Carboplatin. The mechanism studies showed that complexes 1 to 5 could inhibit proteasome activity, induce apoptosis, and inhibit cell proliferation, indicating their great potential as proteasome inhibitors for triple‐negative breast cancer therapy.

show abstract

“…Although some compounds have undergone clinical trial, none have been approved for clinical use [ 83 ]. The great challenge of this approach is to find improved photocytotoxicity by the highest wavelength, providing enhanced light penetration of the tissue [ 82 ].…”

Section: Photoactivity and Thermoactivity Of Cisplatinmentioning

confidence: 99%

The Rationale for “Laser-Induced Thermal Therapy (LITT) and Intratumoral Cisplatin” Approach for Cancer Treatment

Brito

Mancini

Palumbo

et al. 2022

IJMS

View full text Add to dashboard Cite

Cisplatin is one of the most widely used anticancer drugs in the treatment of various types of solid human cancers, as well as germ cell tumors, sarcomas, and lymphomas. Strong evidence from research has demonstrated higher efficacy of a combination of cisplatin and derivatives, together with hyperthermia and light, in overcoming drug resistance and improving tumoricidal efficacy. It is well known that the antioncogenic potential of CDDP is markedly enhanced by hyperthermia compared to drug treatment alone. However, more recently, accelerators of high energy particles, such as synchrotrons, have been used to produce powerful and monochromatizable radiation to induce an Auger electron cascade in cis-platinum molecules. This is the concept that makes photoactivation of cis-platinum theoretically possible. Both heat and light increase cisplatin anticancer activity via multiple mechanisms, generating DNA lesions by interacting with purine bases in DNA followed by activation of several signal transduction pathways which finally lead to apoptosis. For the past twenty-seven years, our group has developed infrared photo-thermal activation of cisplatin for cancer treatment from bench to bedside. The future development of photoactivatable prodrugs of platinum-based agents injected intratumorally will increase selectivity, lower toxicity and increase efficacy of this important class of antitumor drugs, particularly when treating tumors accessible to laser-based fiber-optic devices, as in head and neck cancer. In this article, the mechanistic rationale of combined intratumor injections of cisplatin and laser-induced thermal therapy (CDDP–LITT) and the clinical application of such minimally invasive treatment for cancer are reviewed.

show abstract

Current Status for Oral Platinum (IV) Anticancer Drug Development

Cited by 19 publications

References 65 publications

Axial functionalisation of photoactive diazido platinum(iv) anticancer complexes

Axial functionalisation of photoactive diazido platinum(iv) anticancer complexes

Retracted: Studies of proteasome inhibition and antitumor activity by novel amino acid‐polypyridine‐copper complexes

The Rationale for “Laser-Induced Thermal Therapy (LITT) and Intratumoral Cisplatin” Approach for Cancer Treatment

Contact Info

Product

Resources

About